QUEBEC CITY, Canada, Sept. 18, 2024 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision™, for ADAS, AD and parking applications, is pleased to join Ficosa Internacional SA (“Ficosa”), a top-tier global provider devoted to the research, development, manufacturing and marketing of advanced technology vision, safety, connectivity and efficiency systems for the motor and mobility sectors, at Autosens Europe in Barcelona from October 8-10, 2024. In 2022, LeddarTech and Ficosa established a strategic collaboration to develop a pioneering Intelligent Parking ...

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company’s listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel’s requests and to ensure the Company’s continued listing on Nasdaq.

VISTA, Calif., Sept. 19, 2024 /PRNewswire/ -- NUZEE, INC., ("NUZEE"or the "Company") (NASDAQ：NUZE) a Company with a heritage in specialty coffee and an emerging business in broader consumer food and beverage products, today announced that the Company has signed an endorsement agreement with five sports champions who will endorse the maca beverages (the "Macanuoli") distributed and sold by the Company (the "Agreement"). The five sport champions are Ms. Shurui Li, women's basketball champion; Ms. Chenlin Zhou, trampoline champion; Ms. Lina Yi, tennis champion; Ms. Bingjian Li, bodybuilding champion; and Ms. Shuna Bai, cheerleading champion (the "Sport Champions"). The term of the ...

Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-renown researchers from major research institutions specializing in the treatment of mesothelioma.